We collected the NSCLC samples of those who were treated with anti-PD-L1 or anti-PD-1 immunotherapy and observed the changes in the level of sPD-1 and mPD-1 that would be direct clinical evidence for evaluating the response to ICB and exploring the application in drug therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.